Zepbound tops Wegovy for weight loss in Eli Lilly study

By AP NEWS   |   1 year ago
Zepbound tops Wegovy for weight loss in Eli Lilly study

Eli Lilly's stock rose as they revealed Zepbound's study results, showing higher weight loss compared to Novo Nordisk's Wegovy. Zepbound has garnered $1.3 billion in sales in a short period, showcasing its potential in the market.

Read More

Did you find this insightful?